Acta Neuropsychiatr. 1995 Jun;7(2):52-4. doi: 10.1017/S092427080003756X.
Oince the discovery in the late 1950's of imipramine (Tofranil®), the first tricyclic antidepressant (TCA), and iproniazid, the first monoamine oxidase inhibitor (MAOI), many other TCAs and MAOIs, now being considered the classical antidepressants, have become available. Their effectiveness has been shown in numerous studies, although according to nowadays standards well designed studies (placebo-controlled, defined diagnostic groups, the use of standardized rating scales) with these compounds are relatively scarce. From the early 1980's the so called modern antidepressants have been introduced: the selective serotonin re-uptake inhibitors (SSRIs), the reversible selective monoamine oxidase-A inhibitors (RIMAs) and a variety of other compounds. All these drugs have been registered after their effectiveness had been shown in well designed, placebo-controlled studies. In defining the efficacy of antidepressants, registration authorities consider two aspects important: statistical evidence and clinical relevance.
自 20 世纪 50 年代末期发现丙咪嗪(Tofranil®),即第一种三环抗抑郁药(TCA),以及异烟肼,即第一种单胺氧化酶抑制剂(MAOI)以来,许多其他 TCA 和 MAOIs,现在被认为是经典的抗抑郁药,已经面世。尽管根据现代标准,这些化合物的研究(安慰剂对照、明确的诊断组、使用标准化评分量表)设计良好,但它们的有效性已在许多研究中得到证实。从 20 世纪 80 年代初开始,所谓的现代抗抑郁药问世:选择性 5-羟色胺再摄取抑制剂(SSRIs)、可逆性选择性单胺氧化酶-A 抑制剂(RIMAs)和多种其他化合物。所有这些药物在经过精心设计的安慰剂对照研究证明有效后都已注册。在定义抗抑郁药的疗效时,注册机构认为有两个方面很重要:统计证据和临床相关性。